Printer Friendly
The Free Library
5,677,469 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Zacks Sell List Highlights: Applebee's, Invitrogen, Lamar and Novartis.


CHICAGO -- Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List - Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): Applebee's International Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: APPB APPB Array Processor with Pipelined Bus
APPB Application Builder
) and Invitrogen Corp. (NASDAQ: IVGN). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: Lamar Advertising Co. (NASDAQ: LAMR LAMR Lake Meredith National Recreation Area (US National Park Service)
LAMR Large-Aperture Microwave Radiometer
LAMR Load and Make Ready (pistol shooting) 
) and Novartis AG Novartis AG

Swiss pharmaceutical company. It was formed through the 1996 merger of two Swiss firms: Ciba (see Ciba-Geigy) and Sandoz, a chemical company with interests in pharmaceuticals, nutrition, and agriculture.
 (NYSE NYSE

See: New York Stock Exchange
: NVS NVS - Non-Volatile Storage ). To see the full Zacks #5 Rank List - Stocks to Sell Now visit: http://at.zacks.com/?id=92

Since inception in 1988, the S&P 500 has outperformed the Zacks #5 Rank List Co Stocks to Sell Now by 129.7% annually (11.9% vs. 5.2% respectively). While the rest of Wall Street continued to tout stocks during the market declines of the last few years, Zacks told investors which stocks to sell or avoid.

Here is a synopsis of why APPB and IVGN have a Zacks Rank of #5 (Strong Sell) and should most likely be sold or avoided for the next one to three months. Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe:

Applebee's International Inc. (NASDAQ: APPB) has seen this year's earnings estimates drop eight cents per share Cents per share

The amount of a mutual fund's dividend or capital gains distributions that a shareholder will receive for each share owned.
 over the past three months. Next year's estimates have dropped nine cents per share. The company said that same-store sales Same-store sales is a business term which refers to the revenue generated by one of a retail chain's specific outlets during a certain period of time (often a fiscal quarter or a particular shopping season), compared to an identical period in the past, usually in the previous year.  fell 2.7% in August. Rising energy costs have curtailed consumer spending Consumer demand or consumption is also known as personal consumption expenditure. It is the largest part of aggregate demand or effective demand at the macroeconomic level.  in recent months, with the most impact felt by mid-priced dining chains and retailers.

Invitrogen Corp. (NASDAQ: IVGN) has experienced a drop in analyst estimates. Earnings estimates for this year stand $3.21 per share, down 31 cents from 60 days ago. The company missed revenue projections for the second quarter due to a drop in the company's bioproduction segment on falling prices and flat sales. The segment includes products used for testing in clinical trials and biologic products for use in clinical trials.

Here is a synopsis of why LAMR and NVS have a Zacks Rank of 4 (Sell) and should also most likely be sold or avoided for the next one to three months. Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks:

Lamar Advertising Co. (NASDAQ: LAMR) has been the target of increasing bearishness by analysts. Over the past two months, full year estimates have declined almost 10%. The new consensus estimate calls for 47 cents per share this year. The company reported a 2% drop in second-quarter income as higher interest expense outpaced revenue growth.

Novartis AG (NYSE: NVS) has seen its earnings estimates drop for this year. The current 2006 consensus estimate of $3.06 per share is six cents below the forecast of three months ago. Second-quarter profit only rose 4% from a year ago. Integration costs of acquiring Chiron were one reason profit growth was tepid.

Truly taking advantage of the Zacks Rank requires the understanding of how it works. The free special report; "Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions" is available to provide this insightful background. Download a free copy now to prosper in the years to come at http://at.zacks.com/?id=93

About the Zacks Rank

Since 1988, the Zacks Rank has proven that "Earnings estimate revisions are the most powerful force impacting stock prices." A $10,000 investment in the Zacks Rank list made in 1988 would now be worth $1.8 million - equivalent to a 32.4% annualized annualized

Of or relating to a variable that has been mathematically converted to a yearly rate. Inflation and interest rates are generally annualized since it is on this basis that these two variables are ordinarily stated and compared.
 return! During the 2000-2002 bear market, Zacks #1 Rank stocks gained 43.8%, while the S&P 500 tumbled 37.6%. Also note that the Zacks Rank system has just as many Strong Sell recommendations (Rank #5) as Strong Buy recommendations (Rank #1). Since 1988, Zacks Rank #5 stocks have underperformed the S&P 500 by 145.8% annually (+4.7% vs. +11.6%). Thus, the Zacks Rank system allows investors to truly manage portfolio trading effectively.

Zacks "Profit from the Pros" e-mail newsletter offers continuous coverage of Zacks #1 Rank stocks and highlights those stocks poised to outperform the market. Subscribe to Verb 1. subscribe to - receive or obtain regularly; "We take the Times every day"
subscribe, take

buy, purchase - obtain by purchase; acquire by means of a financial transaction; "The family purchased a new car"; "The conglomerate acquired a new company";
 this free newsletter today by visiting http://at.zacks.com/?id=94

About Zacks

Zacks.com is a property of Zacks Investment Research Zacks Investment Research

A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms.
, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=95

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

(a)The S&P 500 Index ("S&P 500") is a well-known, unmanaged index of the prices of 500 large-company common stocks selected by Standard & Poor's. The S&P 500 includes the reinvestment Reinvestment

Using dividends, interest and capital gains earned in an investment or mutual fund to purchase additional shares or units, rather than receiving the distributions in cash.

1. In terms of stocks, it is the reinvestment of dividends to purchase additional shares.
 of all dividends, no transaction costs Transaction Costs

Costs incurred when buying or selling securities. These include brokers' commissions and spreads (the difference between the price the dealer paid for a security and the price they can sell it).
, and represents the gross returns before management fees.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 26, 2006
Words:948
Previous Article:Bango Announces Ad-Launchpad - Mobile Advertising Initiative Delivers Highly Targeted Results and Helps Eliminate Click Fraud.
Next Article:Next Generation Sport & Event Ticket Management Software Turns Ticket Inventories into Easily Managed Corporate Assets.
Topics:



Related Articles
Zacks.com Features the Following Top Stocks in the Medical Products Industry: Invitrogen, Boston Scientific, Baxter and Guidant.
Zacks Issues Buy Recommendations on the Following 6 Stocks: Advanced Digital, Apollo, Rainbow, Invitrogen, Mylan and Ryland.
Zacks Buy List Highlights: Brightpoint, Tommy Hilfiger, Invitrogen, and Starbucks.
Zacks.com Announces That Lon Juricic Highlights the Following Stocks: Seattle Genetics, ArQule, OSI Pharmaceuticals, and Novartis.
Zacks Buy List Highlights: Black & Decker Corporation, D.R. Horton, Inc., bebe stores, inc., and Invitrogen Corporation.
Zacks Buy List Highlights: Schlumberger Ltd., Timken Co., Chico's FAS, Inc., and Invitrogen Corporation.
Zacks Analyst Blog Highlights: Fisher Scientific, Thermo Electron Corp., Invitrogen, ABI and Waters Corp.
Zacks Sell List Highlights: Lennar Corporation, Urban Outfitters, Applebee's Int'l and Hexcel Corporation.
Zacks Sell List Highlights: Cendant, Sigmatel, Affymetrix and Applebees.
Zacks Sell List Highlights: Landry's, Lithia Motors, Affymetrix Inc and Celgene.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles